Dare Bioscience (DARE)
(Delayed Data from NSDQ)
$0.44 USD
+0.01 (2.22%)
Updated Jun 6, 2024 04:00 PM ET
After-Market: $0.44 0.00 (0.39%) 5:32 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Dare Bioscience, Inc. [DARE]
Reports for Purchase
Showing records 41 - 60 ( 213 total )
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Dare''s IDE Application For Ovaprene Approved by the FDA; Maintain Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
BUY: IDE Approval for a Single-Arm, Open-Label Pivotal Contraceptive Efficacy Study of Ovaprene
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Reports 2nd Quarter - Balance Sheet Rising
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
1Q2022 - Cash Balance and Upcoming Catalysts For Our Biotech Coverage Universe
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
1Q2022 Update - Focus for 2022 Remains on XACIATO and Ovaprene
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Reports 1Q22: $39M in Cash, Shares Out Rise to 84M
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Well Worth the Wait: Dare Inks Partnership With Organon for Xaciato; Reiterate Buy and Target to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
4Q2021 Update - XACIATO''s Market Launch Set For 4Q2022, Raising PT to $17
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Second Partnership Signed, With Potential for More - Reiterate Buy, $11 PT
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z